IMAC Holdings Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Jeff Ervin

Chief executive officer

US$212.5k

Total compensation

CEO salary percentage	94.1%
CEO tenure	9.3yrs
CEO ownership	1.1%
Management average tenure	no data
Board average tenure	3.6yrs

Recent management updates

Recent updates

IMAC Holdings, Inc.'s (NASDAQ:BACK) Business And Shares Still Trailing The Industry

Apr 18

Is IMAC Holdings (NASDAQ:IMAC) Using Debt In A Risky Way?

Oct 12

IMAC expands Florida presence with Fort Pierce Chiropractic acquisition for undisclosed amount

Jun 14

CEO Compensation Analysis

How has Jeff Ervin's remuneration changed compared to IMAC Holdings's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-US$6m
Dec 31 2023	US$213k	US$200k	-US$6m
Sep 30 2023	n/a	n/a	-US$15m
Jun 30 2023	n/a	n/a	-US$18m
Mar 31 2023	n/a	n/a	-US$19m
Dec 31 2022	US$371k	US$371k	-US$12m
Sep 30 2022	n/a	n/a	-US$14m
Jun 30 2022	n/a	n/a	-US$11m
Mar 31 2022	n/a	n/a	-US$11m
Dec 31 2021	US$378k	US$328k	-US$11m
Sep 30 2021	n/a	n/a	-US$8m
Jun 30 2021	n/a	n/a	-US$7m
Mar 31 2021	n/a	n/a	-US$6m
Dec 31 2020	US$253k	US$253k	-US$6m
Sep 30 2020	n/a	n/a	-US$7m
Jun 30 2020	n/a	n/a	-US$7m
Mar 31 2020	n/a	n/a	-US$7m
Dec 31 2019	US$1m	US$238k	-US$6m
Sep 30 2019	n/a	n/a	-US$6m
Jun 30 2019	n/a	n/a	-US$5m
Mar 31 2019	n/a	n/a	-US$4m
Dec 31 2018	US$202k	US$178k	-US$3m
Sep 30 2018	n/a	n/a	-US$2m
Jun 30 2018	n/a	n/a	-US$1m
Mar 31 2018	n/a	n/a	-US$554k
Dec 31 2017	US$195k	US$155k	-US$57k

Compensation vs Market: Jeff's total compensation ($USD212.50K) is below average for companies of similar size in the US market ($USD661.60K).

Compensation vs Earnings: Jeff's compensation has been consistent with company performance over the past year.

CEO

Jeff Ervin (45 yo)

9.3yrs

Tenure

US$212,500

Compensation

Mr. Jeffrey S. Ervin, also known as Jeff, has been the Chairman and Director of IMAC Holdings, Inc. since 2018 and serves as its Chief Executive Officer since 2015. He serves as Independent Director at Cin...

Board Members

Name	Position	Tenure	Compensation	Ownership
Jeffrey Ervin	Chairman & CEO	6.3yrs	US$212.50k	1.08% $ 41.8k
Michael Pruitt	Independent Director	3.6yrs	US$59.30k	0.77% $ 29.8k
Cary Sucoff	Independent Director	3.6yrs	US$59.30k	0.87% $ 33.8k
Matthew Wallis	Director	6.3yrs	US$182.32k	5.08% $ 197.4k
Maurice Evans	Independent Director	3.6yrs	US$59.30k	1.28% $ 49.8k

3.6yrs

Average Tenure

49yo

Average Age

Experienced Board: BACK's board of directors are considered experienced (3.6 years average tenure).

IMAC Holdings Management

Management criteria checks 3/4

Key information

Recent management updates

Insufficient new directors

IMAC Holdings, Inc. Announces Executive Changes

Insufficient new directors

IMAC Holdings, Inc., Annual General Meeting, Jul 05, 2023

IMAC Holdings, Inc., Annual General Meeting, Jul 06, 2022

IMAC Holdings, Inc. Announces Executive Changes

Recent updates

Theralink Technologies, Inc. (OTCPK:THER) cancelled the acquisition of IMAC Holdings, Inc. (NasdaqCM:BACK) in a reverse merger transaction.

IMAC Holdings, Inc. announced delayed annual 10-K filing

Insufficient new directors

IMAC Holdings, Inc. Announces Executive Changes

IMAC Holdings Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement of $2.5 Million for Continued Listing on the Nasdaq Capital Market Under Listing Rule 5550(b)(1)

IMAC Holdings, Inc. announced delayed 10-Q filing

Insufficient new directors

IMAC Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements

IMAC Holdings, Inc. Receive Non-Compliance Letter from Nasdaq

IMAC Holdings, Inc. Announces 1-for-30 Reverse Stock Split to Regain Compliance

Price target decreased by 17% to US$1.25

IMAC Holdings Provides Nasdaq Compliance Update Regarding Minimum Stockholders' Equity Requirement and Minimum Bid Price Requirement

IMAC Holdings, Inc. announced that it has received $4.3 million in funding from Theralink Technologies, Inc. and other investors

IMAC Holdings, Inc., Annual General Meeting, Jul 05, 2023

IMAC Holdings Receives A Non-Compliance Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Theralink Technologies, Inc. (OTCPK:THER) entered into a definitive agreement and plan of merger to acquire IMAC Holdings, Inc. (NasdaqCM:BACK) in a reverse merger transaction.

IMAC Holdings, Inc. announced delayed 10-Q filing

IMAC Holdings, Inc.'s (NASDAQ:BACK) Business And Shares Still Trailing The Industry

Consensus forecasts updated

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$5.00

IMAC Holdings, Inc. Launches E-Commerce Website for Vitamin and Supplement Line

IMAC Holdings Receives Notice from The Nasdaq Stock Market Regarding Minimum Bid Price Requirement

IMAC Holdings, Inc. Announces Completion of Third Cohort of Its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson's Disease

Consensus estimates of losses per share improve by 10%

IMAC Holdings, Inc. Announces Addition of Medical Weight Loss Services to IMAC Regeneration Centers

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

IMAC Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $3.925 million.

IMAC Holdings, Inc. Adds Stretch Services At the Backspace

Price target decreased to US$5.50

IMAC Holdings, Inc. Announces the Launch of Spinal Health and Wellness Products and Supplements

IMAC Holdings, Inc., Annual General Meeting, Jul 06, 2022

IMAC Holdings, Inc. announced delayed annual 10-K filing

IMAC Holdings, Inc. Announces Completion of Second Cohort of Its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson’S Disease

IMAC Holdings, Inc. Announces Executive Changes

Imac Holdings, Inc. Announces Relocates of Growing Clinic in St. Louis Area

Third quarter 2021 earnings released: US$0.068 loss per share (vs US$0.12 loss in 3Q 2020)

Is IMAC Holdings (NASDAQ:IMAC) Using Debt In A Risky Way?

Consensus EPS estimates fall to -US$0.38

Price target decreased to US$3.50

Second quarter 2021 earnings released: US$0.15 loss per share (vs US$0.20 loss in 2Q 2020)

IMAC Holdings, Inc. Announces Initiation of Second Cohort of Its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson’s Disease

IMAC Holdings Launches Acute Care Services for Musculoskeletal Injuries

IMAC Holdings, Inc. (NasdaqCM:IMAC) agreed to acquire Active Medical Center Ltd.

IMAC Holdings, Inc. (NasdaqCM:IMAC) acquired Fort Pierce Chiropractic.

IMAC expands Florida presence with Fort Pierce Chiropractic acquisition for undisclosed amount

Imac Holdings, Inc. Introduces the Back Space - First In-Store Chiropractic and Spinal Care Location Within Walmart

Consensus EPS estimates increase to -US$0.34

Consensus revenue estimates fall to US$14.3m

First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.18 loss in 1Q 2020)

Analysts increase EPS estimates to -US$0.36

We Think IMAC Holdings (NASDAQ:IMAC) Has A Fair Chunk Of Debt

Full year 2020 earnings released: US$0.45 loss per share (vs US$0.84 loss in FY 2019)

Revenue and earnings miss expectations

IMAC Holdings, Inc. Announces Completion of First Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson’s Disease

IMAC Holdings, Inc. Partners with Fortune 500 Company to Launch In-Store Spinal Care

IMAC Holdings, Inc. Adds Regenerative Wound Care Service in Regeneration Centers

New 90-day high: US$1.98

IMAC Holdings, Inc. (NasdaqCM:IMAC) entered into an asset purchase agreement to acquire assets from Willmitch Chiropractic.

IMAC expands Florida presence with Tampa clinic acquisition

New 90-day high: US$1.95

IMAC Holdings, Inc. (NasdaqCM:IMAC) executed a definitive agreement to acquire assets of NCH Chiropractic, PLLC.

IMAC acquires Synergy Healthcare, expanding Florida presence

IMAC Holdings, Inc. Appoints Sheri Gardzina as Chief Financial Officer

New 90-day high: US$1.53

IMAC Holdings, Inc. Completes First Infusion of Stem Cells in Clinical Study for the Treatment of Bradykinesia Due to Parkinson’S Disease

IMAC completes first infusion of stem cells in parkinson’s disease study

IMAC Holdings receives $1.69M PPP loan waiver

IMAC Holdings, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement